MLL/KMT2A Antikörper (AA 3751-3968)

Produktnummer ABIN969286

Dieses Maus Monoklonal-Antikörper erkennt spezifisch MLL/KMT2A in IHC und ELISA. Er zeigt eine Reaktivität gegenüber Human und wurde in 3+ Publikationen erwähnt.

Kurzübersicht für MLL/KMT2A Antikörper (AA 3751-3968) (ABIN969286)

Target: MLL/KMT2A (MLL) (Myeloid/lymphoid Or Mixed-Lineage Leukemia (MLL))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser MLL/KMT2A Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (IHC), ELISA

Klon: 10F8D7

Produktdetails anti-MLL/KMT2A Antikörper

Bindungsspezifität: AA 3751-3968

Verwendungszweck: MLL Antibody

Aufreinigung: Ascitic fluid

Immunogen: Purified recombinant fragment of MLL (aa3751-3968) expressed in E. Coli.

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: ELISA: 1/10000

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Ascitic fluid containing 0.03 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

Referenzen für anti-MLL/KMT2A Antikörper (ABIN969286)

Nigro, Sainati, Leszl, Mirabile, Spinelli, Consarino, Di Cataldo, Magro, Felix, Basso: "Acute differentiated dendritic cell leukemia: a variant form of pediatric acute myeloid leukemia with MLL translocation." in: Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, Vol. 21, Issue 2, pp. 360-2, (2007) (PubMed).

Partida-Pérez, Domínguez, Sánchez-Corona, Castañeda-Cisneros, García-González, López-Cardona, Rivera: "Constitutional duplication 11q23 de novo involving the MLL gene." in: Genetic counseling (Geneva, Switzerland), Vol. 17, Issue 2, pp. 155-9, (2006) (PubMed).

Kadkol, Bruno, Oh, Schmidt, Lindgren: "MLL-SEPT6 fusion transcript with a novel sequence in an infant with acute myeloid leukemia." in: Cancer genetics and cytogenetics, Vol. 168, Issue 2, pp. 162-7, (2006) (PubMed).

Details zu MLL/KMT2A

Target: MLL/KMT2A (MLL) (Myeloid/lymphoid Or Mixed-Lineage Leukemia (MLL))

Andere Bezeichnung: MLL

Hintergrund: Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila). Eukaryotic RNA polymerase II mediates the synthesis of mature and functional messenger RNA. This is a multistep process, called the transcription cycle,that includes five stages: preinitiation, promoter, clearance, elongation and termination. Elongation is thought to be a critical stage for the regulation of gene expression. ELL (11-19 lysine-rich leukemia protein, also designated MEN) functions as an RNA polymerase II elongation factor that increases the rateof transcription by suppressing transient pausing by RNA polymerase II. Also, ELL is thought to regulate cellular proliferation. ELL is abundantly expressed in peripheral blood leukocytes, skeletal muscle, placenta and testis, and has lower expression in spleen, thymus, heart, brain, lung, kidney, liver and ovary.The gene encoding human ELL, which maps to chromosome 19p13.1, is one of several genes which undergo translocation with the MLL gene on chromo-some 11q23 in acute myeloid leukemia. MLL (myeloid/lymphoid leukemia,also designated ALL-1 and HRX) is a 430 kDa protein that regulates embryonal and hematopoietic development.

Gen-ID: 4297

UniProt: Q03164

Pathways: Warburg Effekt